Natixis Advisors LLC Buys 23,921 Shares of Alkermes plc (NASDAQ:ALKS)

Natixis Advisors LLC increased its stake in Alkermes plc (NASDAQ:ALKS) by 190.3% in the third quarter, Holdings Channel.com reports. The institutional investor owned 36,490 shares of the company’s stock after acquiring an additional 23,921 shares during the period. Natixis Advisors LLC’s holdings in Alkermes were worth $1,021,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. V Square Quantitative Management LLC purchased a new position in shares of Alkermes during the 3rd quarter worth approximately $29,000. Signaturefd LLC lifted its stake in shares of Alkermes by 51.2% in the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock valued at $34,000 after purchasing an additional 480 shares during the period. Hexagon Capital Partners LLC boosted its position in shares of Alkermes by 3,841.0% during the second quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock valued at $37,000 after purchasing an additional 1,498 shares in the last quarter. GAMMA Investing LLC grew its stake in Alkermes by 44.4% in the second quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock worth $55,000 after purchasing an additional 703 shares during the period. Finally, Ashton Thomas Private Wealth LLC bought a new position in Alkermes in the second quarter worth $116,000. 95.21% of the stock is owned by institutional investors.

Insider Activity

In other Alkermes news, EVP Craig C. Hopkinson sold 10,471 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $29.53, for a total value of $309,208.63. Following the completion of the transaction, the executive vice president now owns 99,238 shares of the company’s stock, valued at approximately $2,930,498.14. The trade was a 9.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ALKS. Cantor Fitzgerald dropped their target price on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Piper Sandler reissued an “overweight” rating and set a $37.00 price objective (down previously from $38.00) on shares of Alkermes in a research note on Friday, October 25th. Stifel Nicolaus upgraded shares of Alkermes from a “hold” rating to a “buy” rating and upped their price objective for the stock from $25.00 to $36.00 in a report on Tuesday, November 5th. HC Wainwright reiterated a “neutral” rating and set a $37.00 target price on shares of Alkermes in a report on Friday, October 25th. Finally, The Goldman Sachs Group dropped their price target on Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $35.42.

Alkermes Stock Performance

Shares of ALKS opened at $29.25 on Wednesday. The company has a market cap of $4.73 billion, a price-to-earnings ratio of 15.00, a P/E/G ratio of 0.96 and a beta of 0.47. The business’s fifty day simple moving average is $27.95 and its two-hundred day simple moving average is $26.45. Alkermes plc has a 12 month low of $22.22 and a 12 month high of $32.88. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.